KALA - Kala Pharmaceuticals Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript
Kala Pharmaceuticals, Inc. (KALA) Q1 2022 Results Earnings Conference Call May 16, 2022, 08:00 AM ET Company Participants Jill Steier - Executive Director, Investor Relations and Corporate Communications Mark Iwicki - Chairman and Chief Executive Officer Todd Bazemore - President and Chief Operating Officer Kim Brazzell - Head of R&D and Chief Medical Officer Mary Reumuth - Chief Financial Officer Conference Call Participants Christopher Neyor - J.P. Morgan Francois Brisebois - Oppenheimer & Co. Andreas Argyrides - Wedbush Securities Presentation Operator Good morning and welcome to Kala Pharmaceuticals Conference Call to Review its Fourth Quarter 2022 Financial Results. At this time, all participants are in a listen-only mode. Following management's prepared remarks, a Q&A session will be held. As a reminder, this call is being recorded. I would like to turn the call over to Jill Steier, Executive Director, Investor Relations and Corporate Communications for Kala Pharmaceuticals. Please proceed. Jill
For further details see:
Kala Pharmaceuticals, Inc. (KALA) CEO Mark Iwicki on Q1 2022 Results - Earnings Call Transcript